INT96841

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 2001
Last Reported 2008
Negated 0
Speculated 1
Reported most in Body
Documents 9
Total Number 14
Disease Relevance 6.83
Pain Relevance 2.14

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Slc11a1) plasma membrane (Slc11a1) lysosome (Slc11a1)
Anatomy Link Frequency
bladder 3
urinary bladders 1
Slc11a1 (Mus musculus)
Pain Link Frequency Relevance Heat
cytokine 338 99.76 Very High Very High Very High
Inflammatory stimuli 28 97.68 Very High Very High Very High
Inflammation 347 97.20 Very High Very High Very High
action potential duration 1 91.36 High High
Action potential 2 89.04 High High
chemokine 73 83.64 Quite High
tetrodotoxin 1 78.88 Quite High
Inflammatory response 42 67.76 Quite High
antagonist 3 44.80 Quite Low
imagery 16 37.12 Quite Low
Disease Link Frequency Relevance Heat
Toxoplasmosis 9 99.36 Very High Very High Very High
INFLAMMATION 417 97.36 Very High Very High Very High
Targeted Disruption 14 96.04 Very High Very High Very High
Coronary Artery Disease 4 95.30 Very High Very High Very High
Infection 98 95.16 Very High Very High Very High
Sprains And Strains 26 95.12 Very High Very High Very High
Overactive Bladder 67 92.48 High High
Bladder Cancer 144 91.56 High High
Cancer 273 89.28 High High
Necrosis 22 88.80 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In order to elucidate the target of Bcg-3 action, the fraction was applied to a tetraethylammonium-pretreated preparation.
Regulation (target) of Bcg-3
1) Confidence 0.36 Published 2001 Journal Braz. J. Med. Biol. Res. Section Abstract Doc Link 11449308 Disease Relevance 0.08 Pain Relevance 0.21
MRS participated in its design, carried out the animal experiments, removed the tissues, extracted the RNA, performed suppression subtractive hybridizations, and performed sequence alignments; HLH participated in the design of the study regarding SSHs and target validation; CS treated the animals with BCG; CAD was responsible for the animal husbandry; MLL consulted RS regarding HLA, NADPH, and helped drafting the manuscript; MAI participated in the experimental design and helped drafting this manuscript; MAO consulted RS regarding clinical implications of BCG treatment, data interpretation, and helped drafting the manuscript; W-RW consulted RS regarding uroplakins, data interpretation, and helped drafting the manuscript.
Spec (implications) Regulation (implications) of BCG associated with coronary artery disease
2) Confidence 0.35 Published 2007 Journal BMC Cancer Section Body Doc Link PMC2212656 Disease Relevance 0.21 Pain Relevance 0
It has been demonstrated that when compared to control BCG, rBCG-S1PT is able to elicit a Th1-driving effect on the immune response induced against mycobacterial proteins [10].
Regulation (control) of rBCG
3) Confidence 0.20 Published 2008 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2647907 Disease Relevance 0.66 Pain Relevance 0.09
It has been demonstrated that when compared to control BCG, rBCG-S1PT is able to elicit a Th1-driving effect on the immune response induced against mycobacterial proteins [10].
Regulation (control) of BCG
4) Confidence 0.17 Published 2008 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2647907 Disease Relevance 0.65 Pain Relevance 0.09
All these cells also release cytokines which then regulate BCG response [16].
Regulation (regulate) of BCG associated with cytokine
5) Confidence 0.17 Published 2007 Journal BMC Immunol Section Body Doc Link PMC1891101 Disease Relevance 0.51 Pain Relevance 0.26
Because IL-4, IL-6, IL-13 and NRAMP are very important in immunity to toxoplasmosis and could play a pathogenic role in the inflammatory process we observed, mice without IL-4, IL-6, IL-13, or Nramp, infected for shorter times, were also studied to determine whether these cytokines or immune processes were necessary and sufficient for the perivascular cuffing and meningeal and parenchymal abnormalities we had observed.
Regulation (important) of NRAMP associated with inflammation, congenital anomalies, toxoplasmosis and cytokine
6) Confidence 0.15 Published 2008 Journal J Neuroinflammation Section Body Doc Link PMC2588578 Disease Relevance 1.22 Pain Relevance 0.23
To determine whether intravesical BCG treatment would alter bladder cytokine gene expression, we used chromatin immunoprecipitation combined with Q-PCR.
Regulation (alter) of BCG in bladder associated with cytokine
7) Confidence 0.12 Published 2007 Journal BMC Immunol Section Body Doc Link PMC1891101 Disease Relevance 0.21 Pain Relevance 0.28
It has also been discovered that IL-10 is not necessary for the antitumor effect of BCG, as we observed no difference on survival between C57BL/6 wild-type and IL-10-/- mice.
Regulation (effect) of BCG
8) Confidence 0.10 Published 2008 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2647907 Disease Relevance 1.05 Pain Relevance 0.27
This preclinical study was designed to compare the modulatory effects of BCG and rBCG-S1PT on bladder TNF-?
Regulation (effects) of BCG in bladder
9) Confidence 0.10 Published 2008 Journal J Exp Clin Cancer Res Section Abstract Doc Link PMC2647907 Disease Relevance 0.56 Pain Relevance 0.03
To determine the time course of gene-expression in urinary bladders in response to chronic intravesical instillation of saline, BCG, TNF-?
Regulation (response) of BCG in urinary bladders
10) Confidence 0.09 Published 2008 Journal BMC Immunol Section Body Doc Link PMC2262873 Disease Relevance 0.29 Pain Relevance 0
In addition, several of the BCG-specific genes are related with calcium and ?
Regulation (several) of BCG-specific
11) Confidence 0.09 Published 2008 Journal BMC Immunol Section Body Doc Link PMC2262873 Disease Relevance 0.08 Pain Relevance 0
CHIP/Q-PCR results indicate a differential up regulation of this family between acute and chronic BCG (Figure 13).


Regulation (regulation) of BCG
12) Confidence 0.07 Published 2007 Journal BMC Immunol Section Body Doc Link PMC1891101 Disease Relevance 0.24 Pain Relevance 0.42
All of these cells also release cytokines that may further regulate the BCG response [16].
Regulation (regulate) of BCG associated with cytokine
13) Confidence 0.05 Published 2008 Journal BMC Immunol Section Body Doc Link PMC2262873 Disease Relevance 0.51 Pain Relevance 0.22
This preclinical study was designed to compare the modulatory effects of BCG and rBCG-S1PT on bladder TNF-?
Regulation (effects) of rBCG in bladder
14) Confidence 0.05 Published 2008 Journal J Exp Clin Cancer Res Section Abstract Doc Link PMC2647907 Disease Relevance 0.56 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox